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BACKGROUND: Recurrent or metastatic cervical cancer represents an aggressive malignancy with a high rate of locoregional and distant
failure. Therefore, we evaluated the three-drug combination of paclitaxel–ifosfamide–cisplatin (TIP).
METHODS: Systemic chemotherapy-naive patients with advanced metastatic/relapsed cervical cancer and a World Health Organization
(WHO) performance status (PS) of 0–2 were eligible. TIP chemotherapy doses were paclitaxel 175mgm
 2 on day 1, ifosfamide
2.5gm
 2 on days 1þ2, and cisplatin 40mgm
 2 on days 1þ2, with prophylactic granulocyte-colony stimulating factor.
RESULTS: A total of 42 patients with recurrent/metastatic cervical cancer are evaluable for response and toxicity: median age:
56 (25–74) years; PS: 1 (0–2); histologies – squamous: 35, adenosquamous: 5, and adenocarcinoma: 2. Responses were overall
response rate (RR): 62% (95% confidence interval (CI): 47.3–76.7%), with complete response (CR): 26% (95% CI: 12.7–39.3%),
and partial response (PR): 36% (95% CI: 21.5–49.9%). Responses according to the relapse site were overall RR: 32% (95% CI:
13.7–50.3%) within previously irradiated pelvis vs 75% (95% CI: 57.7–92.3%) in extra-pelvic sites. Median time to progression (TTP)
was 7 (range, 2–34þ) months and median overall survival (OS) was 16.5 (range, 3–36þ) months. Toxicities included grade 3–4
neutropenia: 83% (21% febrile neutropenia), grade 3–4 thrombocytopenia: 9%, no grade 3 neuropathy (35% grade 2), grade 2
asthenia/fatigue 15%, and no treatment-related deaths.
CONCLUSION: TIP is an active regimen with acceptable toxicity in advanced/relapsed cervical cancer.
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Paclitaxel represents an established active cytotoxic agent against a
wide variety of advanced solid tumours, including gynaecological
cancers such as ovarian, uterine, and cervical malignancies.
Beyond its early documented activity in relapsed ovarian cancer
(Eisenhauer et al, 1994), there are a small number of studies
confirming its activity in advanced endometrial carcinoma
(Lissoni et al, 1996). Single-agent paclitaxel has shown an initial
17% activity in advanced cervical cancer at a dose of 170mgm
 2 in
24-h infusion (Thigpen et al, 1995; McGuire et al, 1996), whereas
subsequent doses of 250mgm
 2 over 3h with granulocyte-colony
stimulating factor (G-CSF) support yielded response rates (RRs) of
25% (Kudelka et al, 1997). Until now, cisplatin has been the most
active cytotoxic drug in advanced cervical cancer, and randomised
studies applying combinations of first-generation cytotoxic agents
with cisplatin had not shown any advantage over single-agent
cisplatin. However, a large randomised study conducted by the
Gynecologic Oncology Group (GOG) showed that the cisplatin–
ifosfamide combination yielded a 31% RR, significantly higher
than the cisplatin–mitolactol combination or cisplatin mono-
therapy, whereas the median time to progression (TTP) was not
prolonged significantly: 4.6 vs 3.2 months (Omura et al, 1997).
Ifosfamide represents another very active antineoplastic agent
in advanced/relapsed cervical cancer (Sutton et al, 1993). The
combination of paclitaxel–cisplatin has yielded very encouraging
RRs: 50% in phase II studies (Papadimitriou et al, 1999; Rose et al,
1999). Moreover, the three-drug combination of paclitaxel–
ifosfamide–cisplatin (TIP) has been very active in advanced/
metastatic cervical cancer that has relapsed after surgery±
radiotherapy (Zanetta et al, 1999), whereas it has shown an 84%
RR with 16% pathological CR when applied as neoadjuvant
chemotherapy before radical surgery in stages IB2–IVA (Zanetta
et al, 1998).
A phase I study of TIP conducted by our group in various
advanced solid tumours has shown the feasibility of administering
full doses of each drug with the aid of G-CSF and has established
the recommended doses (Kosmas et al, 2000a), and subsequent
phase II studies in advanced non-small-cell (Kosmas et al, 2000b)
and small-cell lung cancer (Kosmas et al, 2001) have confirmed the
feasibility and high anti-tumour activity of the combination.
The aim of this study was to evaluate the feasibility and activity
of the TIP regimen in patients with locoregionally relapsed (after
radiotherapy±surgery) and/or metastatic cervical cancer.
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Patient selection
Consecutive patients with histologically confirmed cervical cancer
that had relapsed after previous pelvic radiotherapy±surgery or
with distant metastases at presentation, which were referred to
three collaborating Medical Oncology units, were candidates for
treatment with the TIP chemotherapy regimen. Eligibility included
the following: (i) patients aged between 18 and 75 years with
histologically confirmed cervical cancer not potentially curable by
other local measures such as salvage surgery or radiotherapy; (ii) a
World Health Organization (WHO) performance status (PS) of
p2; (iii) life expectancy of X3 months; (iv) adequate haemato-
poietic (ANC 41500ml
 1, PLT 4100000ml
 1), liver (bilirubin
o1.5mg per 100ml, AST/ALT o2 upper normal limit (nl),
unless caused by tumour and serum albumin 43.0g per 100ml),
and renal function (BUN and creatinine o1.5nl; nl¼1.5mg per
100ml in our laboratory or creatinine clearance 460mlmin
 1);
(v) no previous systemic chemotherapy (radiosensitising chemo-
therapy with weekly cisplatin was allowed); (vi) absence of
active coronary artery disease (over the last 12 months), unstable
diabetes mellitus, or peripheral neuropathy Xgrade 2 by the
WHO criteria; and (vii) presence of bi-dimensionally measurable
disease outside a previously irradiated field, unless there was
definite evidence of progression at this site. Patients with isolated
progression within the pelvis after radical radiotherapy±surgery
had to show a X50% increase in the sum of the products of
residual lesions at least 3 months after completion of radiotherapy.
Patients with brain metastases were excluded from this study. The
study was approved by the Institutional Review Board of the
participating institutions, and informed consent was obtained
from each patient before study entry according to Institutional
policies.
Treatment schedule
Eligible patients were treated as follows: paclitaxel was adminis-
tered at 175mgm
 2 over 1–3h by intravenous (i.v.) infusion on
day 1, after pre-medication consisting of dexamethasone 20mg,
dimethindene maleate (Fenistil) 4mg, and ranitidine 50mg, all
administered i.v. 1h before paclitaxel administration (Tsavaris
et al, 1997). Ifosfamide was administered at 5.0gm
 2 i.v. over
1h divided into 2 days (days 1, 2: 2.5gm
 2 per day; total dose
5.0gm
 2), together with mesna uroprotection, at 40% of the
ifosfamide dose, given i.v., together with ifosfamide infusion, and
at 3 and 6h thereafter. Cisplatin was administered at 80mgm
 2 i.v.
over 30min, fractionated for 2 days (days 1, 2: 40mgm
 2 per
day; total dose 80mgm
 2) with adequate vigorous pre- and post-
hydration, mannitol and furosemide diuresis, and electrolyte
replacement, 20mequiv. potassium chloride and 8mequiv. magne-
sium sulphate per liter of post-hydration solution (0.9% normal
saline (N/S) or 1/2 N/Sþ5% dextrose (D5/w)). The chemotherapy
schedule (TIP) was recycled every 21 days.
Supportive care
Standard anti-emetic medication included ondansetron 24mg or
granisetron 3mg i.v. 1h before chemotherapy at 12h, 8mg i.v./p.o.
or 3mg i.v./1mg p.o., respectively, on days 1 and 2 and post-
chemotherapy ondasetron 8mg t.i.d./p.o. or granisetron 1mg p.o.
on days 3–5. Dexamethasone 20mg i.v. was administered 1h
before chemotherapy (day 1 as paclitaxel pre-medication as well)
on days 1 and 2 and post-chemotherapy 4mg t.i.d. or methyl-
prednisolone 16mg b.i.d/p.o. on days 3–5 (Kosmas et al, 2000a).
Haematopoietic growth factors included G-CSF 5mgkg
 1 s.c.
(filgrastim or lenograstim) from day 4 until WBC of X10000ml
 1
and recombinant human erythropoietin (rh-Epo) of 10000IU s.c./
t.i.w or 30,000IU Epoetin-beta or 40000IU Epoetin-alpha 
1/week (not on the days of chemotherapy) whenever the haemo-
globin (Hb) value dropped p10.5g per 100ml and continued until
Hb X12g per 100ml.
Dose modifications for toxicity
The prerequisites for dose modifications were set as follows: (i)
any episode of grade 4 neutropenia of 47 days duration, (ii) any
episode of febrile Xgrade 3 neutropenia, (iii) any episode of grade
4 thrombocytopenia, (iv) any non-haematologic grade 3 or 4
toxicity excluding nausea and vomiting, musculoskeletal and
arthritic pain (myalgia/arthralgia syndrome), and alopecia.
The following guidelines were applied with respect to dose
reductions for toxicity: (i) For neutropenia, meeting the afore-
mentioned criteria, paclitaxel and ifosfamide doses were reduced
by 20% in subsequent cycles and if toxicity reappeared after a total
of 40% reduction from the starting dose in consecutive cycles,
treatment was stopped; however, the patient was evaluable for
toxicity and response. (ii) For thrombocytopenia, reduction of
cisplatin by 20% was applied in addition to paclitaxel and
ifosfamide dose reductions as specified for neutropenia. (iii) For
Xgrade 3 mucositis, the doses of paclitaxel and ifosfamide were
reduced by 20% in subsequent cycles. (iv) For neuropathy, Xgrade
3 treatment was interrupted. (v) For renal toxicity, X3 grade
toxicity (serum creatinine elevations 43 normal) treatment was
withheld until recovery (serum creatinine o1.8mg per 100ml)
with cisplatin and ifosfamide administered with further hydration,
mannitol diuresis, and hospitalisation in subsequent cycles. (vi)
For Xgrade 3 CNS toxicity (ifosfamide encephalopathy), the dose
of ifosfamide was reduced by 20% and more hydration with
bicarbonates was anticipated in subsequent cycles. In the case
that encephalopathy reappeared, ifosfamide was omitted from
subsequent cycles.
In the case in which blood counts had not recovered to
ANC X1.500ml
 1 and PLT X100.000ml
 1 on the day of therapy,
treatment was withheld until recovery, and after a maximum delay
of 2 weeks, no further therapy was administered.
Pretreatment, follow-up studies, and response evaluation
Tumour measurements were determined by physical examination
and by the specific radiological test that documented measurable
disease before treatment. Before the first chemotherapy cycle, a
detailed clinical and gynaecological (pelvic) examination, followed
by CT scans of the chest/abdomen/pelvis and radionuclide bone
scintigraphy, was carried out in all patients. Computed tomo-
graphy scans of the brain were carried out in the case of suspected
brain metastases. Blood counts were checked weekly after
each cycle (days 8 and 15) or more frequently in the case of grade
3–4 haematologic toxicity. Evaluation of response was carried
out every three cycles of therapy. Patients experiencing toxic death
despite objective responses at measurable sites would be
categorised as treatment failures. Complete response (CR) is
defined as the disappearance of all signs and symptoms of disease
for at least 1 month, with the documented disappearance of all
known lesions by physical examination, X-rays, CT scans, bone
scans, and the development of no new lesions. Partial response
(PR) indicates a decrease of X50%(compared with pretreatment
measurements) in the sum of the products of the two largest
perpendicular diameters of all measurable lesions and no
concomitant growth of new lesions for at least 1 month. There
could be no deterioration of symptoms or PS unless secondary to
drug toxicity. Stable disease indicates a decrease of o50% or an
increase in tumour size o25% over the original measurements.
There could be no deterioration of symptoms or PS unless
secondary to drug toxicity. Progressive disease (PD) was defined as
an increase of X25% over the original measurements.
TIP in cervical cancer
C Kosmas et al
1060
British Journal of Cancer (2009) 101(7), 1059–1065 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sFull staging evaluation had to be carried out, as reported above,
before treatment initiation. Follow-up disease evaluation was
carried out at approximately 3-month intervals after the end of
treatment.
Statistical methods
Patients who received at least two cycles of treatment were
evaluable for response, unless there was definite evidence of
progression after the first cycle for them to be categorised as
having PD, and patients who received at least one cycle of
treatment were evaluable for toxicity. Response duration was
measured from the day of its initial documentation until PD; TTP
was calculated from study entry until evidence of PD; OS was
measured from the day of entry until last follow-up or death. The
95% confidence intervals (CIs) for RRs were calculated from
the binomial distribution (Cox, 1970). Survival was estimated by
the product-limit method of Kaplan–Meier (Kaplan and Meier,
1958). The trial was designed as a phase II study, with RR as the
main end point. According to Simon’s (1989) two-stage design
(Simon, 1989), with a sample size of n¼40, the study has an 80%
power to accept the hypothesis that true RR is 450%, and a
P value o0.05 to reject the hypothesis that the true RR is o30%, if
o19 responses occur. At the first stage, if o5 responses occurred
out of the initial 16 patients, the study would conclude that the
anticipated RR was o30% and terminate, with a power 490%.
The study was supervised by the Data Safety Monitoring Board
(DSMB) for severe and unacceptable toxicities, and no concern was
raised by the investigators and the DSMB regarding safety and
efficacy, particularly during the first stage.
RESULTS
Patients’ characteristics
Between June 2003 and August 2008, 42 patients with relapsed/
metastatic cervical cancer were treated with the TIP chemotherapy
regimen. Final data analysis was carried out in March 2009 after
all patients entered had completed the planned six cycles of
chemotherapy or had interrupted treatment as a result of disease
progression or unacceptable toxicity. Patient characteristics and
demographics are provided in Table 1. Median age was 56 years
(range, 25–74), and 93% had a WHO-PS of 0 or 1, with 7% of
patients having a WHO-PS of 2. Overall, 59.5% of patients
presented with an advanced FIGO stage III or IV (16.7% with
metastatic stage IVB disease). A total of 40.5% of patients had
undergone radical hysterectomy and pelvic lymphadenectomy
earlier, and 79% had undergone an earlier radical radiotherapy in
the pelvis. Overall, 17% of patients had histologies other than
squamous carcinoma (12% adenosquamous carcinoma and 5%
adenocarcinoma).
Response to treatment and survival
Response to TIP chemotherapy was as follows: overall RR: 26 out
of 42 (62%, 95% CI: 47.3–76.7%), with CR: 11 out of 42 (26%, 95%
CI: 12.7–39.3%) and PR: 15 out of 42 (36%, 95% CI: 21.5–49.9%).
Stable disease was observed in 11 out of 42 patients (26%, 95% CI:
12.7–39.3%) and PD in 5 out of 42 patients (12%, 95% CI:
2.2–21.8%). Responses were further subdivided according to
disease site, that is, within previously irradiated pelvis vs outside
pelvis and/or distant sites, and were as follows: overall RR: 8 out of
25 (32%, 95% CI: 13.7–50.3%) in pelvic sites vs 18 out of 24 (75%,
95% CI: 57.7–92.3%) (P¼0.041) in extra-pelvic sites (as seven
patients had measurable disease at both irradiated pelvis and
extra-pelvic sites) (see also Table 2). Moreover, RR after chemo-
radiation vs others was 15 out of 28 (53.5%, 95% CI: 35–72%) vs 11
out of 14 (78.6%, 95% CI: 57.1–100%), respectively (P¼NS
(nonsignificant), as a result of small numbers). The median
duration of response (for CRþPR patients) was 6.5 months and
median TTP was 7 months (range, 2 to 34þ), whereas the median
OS was 16.5 months (range, 3 to 36þ) (Figure 1).
Compliance with treatment
A total of 224 treatment cycles (median: 6 cycles; range, 2–6,
mean: 5.33 cycles) were administered. Six patients did not
complete the planned six cycles as a result of PD detected after
Table 1 Patient characteristics
Characteristic No. %
Number of patients 42 100
Age (years)
Median (range) 56 (25–74)
Performance status (WHO)
02 3 5 5
11 6 3 8
23 7
Histology
Squamous 35 83
Adenosquamous 5 12
Adenocarcinoma 2 5
Previous treatment
Surgery alone 2 4
Surgery-radiation 5 12
Surgery-chemoradiation 10 24
Concurrent chemoradiation 18 43
None 7 17
Sites of tumour involvement
Within prior radiation field (pelvis) 18 43
Outside prior radiation field 17 40
Both 7 17
Metastatic sites
Lymph nodes 36 86
Pelvic mass 26 62
Lung 12 29
Liver 3 7
Bone 2 4
No. of sites with tumour involvement
11 5 3 6
22 3 5 5
434 9
Abbreviation: WHO¼World Health Organization.
Table 2 Response to TIP regimen by disease site
All
patients
Within irradiated
pelvis
Outside irradiated
pelvis
Response No. (%) No. (%) No. (%)
CR 11 (26) 1 (4) 10 (42)
PR 15 (36) 7 (28) 8 (33)
SD 11 (26) 12 (48) 6 (25)
PD 5 (12) 5 (20) 0 (0)
Total 42 (100) 25 (100) 24 (100)
Abbreviations: CR¼complete response; PD¼progressive disease; PR¼partial
response; SD¼stable disease; TIP¼paclitaxel–ifosfamide–cisplatin.
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sthe third cycle in five and after the second cycle in one patient.
Four more patients did not complete the planned six cycles as a
result of: two dose reductions in successive cycles for haematologic
toxicity (as defined above) in two patients after the fourth and fifth
cycle, and treatment omission for renal toxicity in two patients
(after cycles 2 and 4).
Toxicities
Haematologic and non-haematologic toxicity data for all patients
enrolled are summarised in Tables 3 and 4, respectively. Haemato-
logic toxicities (Table 3) consisted primarily of grade 3–4
neutropenia in 83% (57% grade 4) of patients, despite the use of
prophylactic G-CSF administration, whereas grade 3–4 thrombo-
cytopenia was encountered in 9% (2% grade 4) of patients. Febrile
neutropenia was observed in 9 out of 42 (21%) of patients, with 5
of them developing more than one episode. All febrile neutropenic
events were managed successfully in the in-patient or outpatient
setting by broad-spectrum antibiotics, and there were no treat-
ment-related deaths.
Non-haematologic toxicities (Table 4) consisted primarily of
grade 2–3 nausea and vomiting in 13 out of 22% patients, grade
1–2 myalgia/arthralgia in 17 out of 33%, and mild grade 1
mucositis in 22% with no Xgrade 2. Grade 2 peripheral
neuropathy was observed in 35% of patients and usually resolved
to pgrade 1 in the majority.
Dose intensity analysis
The administered median dose intensities for each drug of the TIP
combination were as follows: for paclitaxel 52.0mgm
 2week
 1
(range: 48.3–58.3) or 89.2% (range: 82.2–100%) of the planned
dose, for ifosfamide 1.5gm
 2week
 1 (range: 1.2–1.67) or
89.8% (range: 71.8–100%) of the planned dose, and for cisplatin
23.0mgm
 2week
 1 (range: 19.6–26.6) or 86.7% (range: 73.7–
100%) of the planned dose (Table 5). Therefore, patients received
485% of the planned dose intensity for all cytotoxic drugs in the
regimen.
DISCUSSION
Despite significant efforts invested in clinical investigation over the
past two decades, the treatment options for patients with locally
recurrent/advanced after radiotherapy±surgery or de novo meta-
static cervical cancer remain limited, and survival for these
patients has remained notoriously unchanged and disappointing,
with almost no long-term survivors. Cisplatin-based chemo-
therapeutic regimens in combination with other active drugs
have resulted in both higher RRs and prolonged PFS or OS when
compared with single-agent cisplatin, as verified in large phase III
randomised trials (Omura et al, 1997; Moore et al, 2004; Long et al,
2005). However, the effect of the traditional cisplatin-based
combinations in the outcome of recurrent/advanced or metastatic
cervical cancer seems to be limited. Therefore, the search for newer
two-drug or three-drug cisplatin-based combinations is warranted.
Paclitaxel represents an established active cytotoxic agent
against advanced/metastatic cervical cancer at doses between
170 and 250mgm
 2 (McGuire et al, 1996; Kudelka et al, 1997).
Ifosfamide represents an oxazaphosphorine alkylating agent
that has yielded an 11% RR in pretreated and a 15.7% RR in
chemotherapy-naive patients with advanced cervical cancer,
whereas at high doses of 3.5gm
 2 5 days, a 50% RR in untreated
patients was observed (Cervellino et al, 1990). Moreover, the
doublet combinations of ifosfamideþcisplatin and paclitaxelþ
cisplatin (TP) have shown improved RRs and PFS over single-
agent cisplatin in two phase III GOG studies (Omura et al, 1997;
Moore et al, 2004).
Preclinical data have shown that paclitaxel intensifies the cell-
killing effects of chemically induced DNA damage by alkylating
agents and cisplatin, provided that paclitaxel precedes these agents
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Figure 1 Overall survival data of cervical cancer patients treated with
TIP.
Table 3 Haematologic toxicities (WHO grade) for TIP
WHO grade (% of patients, all cycles)
Toxicity 01234
Leukopenia 0 5 11 30 54
Neutropenia 0 4 13 26 57
Thrombocytopenia 15 48 28 7 2
Anaemia 45 24 24 7 0
Febrile Neutropenia 21%
Abbreviations: TIP¼paclitaxel–ifosfamide–cisplatin; WHO¼World Health
Organization.
Table 4 Non-haematologic toxicities (WHO grade) for TIP
WHO grade (% of patients, all cycles)
Toxicity 0 1 2 3 4
Nausea and vomiting 24 41 13 22 0
Mucositis 72 28 0 0 0
Myalgia/arthralgia 50 17 33 0 —
Neurologic
Peripheral 14 51 35 0 0
C N S 7 4 2 4200
Infection 93 5020
Diarrhoea 51 18 31 0 —
Allergy 93 7000
Alopecia 0 0 15 85 0
Asthenia/fatigue 16 38 31 15 —
Cardiac 98 2000
Renal 96 2200
Haematuria 98 2000
Electrolyte
a 9 55000
Abbreviations: CNS¼central nervous system; TIP¼paclitaxel–ifosfamide–cisplatin;
WHO¼World Health Organization.
aElectrolyte toxicity refers to serum potassium
(K
+) and magnesium (Mg
2+) drop.
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paclitaxel has shown enhanced activity and possibly synergistic
effects when combined with alkylating agents, cyclophosphamide
and ifosfamide (Bunnell et al, 1998), or cisplatin (Rowinsky et al,
1993). The proposed mechanisms of in vitro and in vivo synergism
are provided in Figure 2 (see also Lind et al, 1989; Reed et al,
1995).
Establishment of the recommended doses of each agent,
paclitaxel, ifosfamide, and cisplatin, was based in our previous
phase I study of TIP (Kosmas et al, 2000a); however, we elected
to reduce the recommended dose of cisplatin from 100 to
80mgm
 2 (divided over 2 days) to compensate for imminent
toxicity, particularly in patients exposed to previous pelvic
radiotherapy.
The TIP regimen as applied in this study yielded efficacy and
survival figures comparable with those obtained in three other
published studies (Zanetta et al, 1999; Dimopoulos et al, 2002;
Choi et al, 2006). The study by Zanetta et al (1999) evaluated a
mixed population of 45 patients with inoperable advanced and/or
metastatic cervical carcinoma, with 14 out of 45 patients having
never had pelvic irradiation earlier, and 10 patients who under-
went locoregional surgery with radical hysterectomy/pelvic±
paraortic lymphadenectomy after a favourable response to TIP
essentially having the role of neoadjuvant/induction chemo-
therapy. An ORR was seen in 67% of patients with a 75% RR in
non-irradiated and 52% RR in previously irradiated pelvic areas.
Overall survival at the time of publication for patients with CR, PR,
and non-responders was 13þ,9 þ, and 6 months, respectively.
Although the authors report a high incidence, that is, 91%, of grade
3–4 myelotoxicity, they do not provide any data on the incidence
of febrile neutropenia. Moreover, prophylactic G-CSF was not
routinely administered to all patients, but only as secondary
prophylaxis after significant myeloid lineage toxicity, and the
regimen was modified to a 50-mgm
 2 dose of cisplatin in patients
who had undergone pelvic radiotherapy earlier (vs 75mgm
 2 for
non-irradiated patients) with a 24-h infusion of paclitaxel
175mgm
 2 and ifosfamide 5.0gm
 2. In a more recent randomised
phase II study of the same group evaluating neoadjuvant TIP
vs TP, aiming towards radical surgery in chemotherapy- and
radiotherapy-naive patients, the incidence of grade 3–4 neutro-
penia was 76% for TIP vs 26% for TP without routine prophylactic
G-CSF (Lissoni et al, 2009).
In the study by Dimopoulos et al (2002), ORR was 46%
(CR¼19%þPR¼27%) with an 11.5-month median response
duration, 8.3-month median TTP, and 18.6-month median OS. It
should be noted that despite the apparently adequate doses applied
(paclitaxel 175mgm
 2, cisplatin 75mgm
 2, and ifosfamide
4.5gm
 2, divided over 3 days), the regimen was less intense, as
it was administered at an intended 4-week interval, contrary to the
usual 3-week interval pertaining to our and the other published
studies so far (Zanetta et al, 1999; Choi et al, 2006). Despite routine
G-CSF prophylaxis, a 26% incidence of grade 4 neutropenia was
reported.
In the more recently published study by Choi et al (2006), ORR
was 46.7% (CR¼4.4%þPR¼42.2%) with a median TTP of
8.0 months and OS of 19 months. However, in this latter study, an
appreciable number of patients, 17 out of 45 (38%), received TIP
as second-line chemotherapy after failure of first-line cisplatinþ
5-FU, and this group fared significantly worse in terms of ORR
and survival compared with those who received TIP as first-line
chemotherapy (Choi et al, 2006). Drug doses in this study were
lower than those in all other published studies, namely paclitaxel
135mgm
 2, cisplatin 50mgm
 2, and ifosfamide 3.0gm
 2, divided
over 3 days at 3-week intervals, justified by the authors as a result
of previous pelvic irradiation in the majority of patients (96%).
However, only seven episodes of febrile neutropenia were recorded
(out of 253 cycles) without routine prophylactic G-CSF, and the
incidence of 4grade 2 peripheral neuropathy was 21%, the latter
rather as a result of previous extensive systemic cisplatin
chemotherapy.
Our results, with an ORR of 62% (CR¼26%þPR¼36%), a
median TTP of 7 months, and a median OS of 16.5 months, are
close to those obtained by Zanetta et al (1999), and compare
favourably with those obtained in the other two studies
(Dimopoulos et al, 2002; Choi et al, 2006). Despite a higher
proportion of patients who underwent pelvic irradiation earlier
(79%), compared with the Italian study (Zanetta et al, 1999) (69%),
our results were not inferior, as the doses of drugs applied were
not compromised, and this was reflected by the 21% incidence of
febrile neutropenia despite routine prophylactic G-CSF. However,
the majority of these febrile neutropenic episodes were managed
uneventfully in the outpatient setting. Despite the limitations of
inter-study comparisons, ORR were inferior in the studies by
Dimopoulos et al (2002) and Choi et al (2006), presumably as
a result of significant under-dosing, an arbitrarily selected
lower dose intensity in the first study (4-week interval) and lower
doses of drugs in the second study. In the latter study, significant
under-dosing was reflected by the low incidence of grade 3–4
neutropenia, that is 11% (Choi et al, 2006). However, despite the
higher ORR in our study, PFS and OS figures were comparable
Table 5 Dose intensity analysis of TIP in cervical cancer
Drug
Planned dose
(every 3 weeks)
Actual mean DI
(mgm
 2week
 1) (range)
Planned DI
(mgm
 2week
 1)
%o f
planned DI
Paclitaxel 175mgm
 2 52.0 (48.3–58.3) 58.3 89.2 (82.2–100)
Ifosfamide 5.0gm
 2 1.50 (1.2–1.67) 1.67 89.8 (71.8–100)
Cisplatin 80mgm
  2 23.0 (19.6–26.6) 26.6 86.7 (73.7–100)
Abbreviations: DI¼dose intensity; TIP¼paclitaxel–ifosfamide–cisplatin.
Cisplatin-induced DNA
damage
Oxazophosphorine*-induced DNA
damage
Kinking of DNA
double helix
Prevention of DNA strand
separation and unwinding
Major Major
Minor
Repair of the DNA lesion
(drug resistance)
Nucleotide excision
repair pathway
Base-mismatch
repair pathway
Paclitaxel
Energy-
dependent
Figure 2 Paclitaxel inhibition of repair of the DNA damage induced by
cisplatin and oxazaphosphorine *(cyclophosphamide or ifosfamide) cyto-
statics (adapted and modified from Reed et al, 1995).
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presumably as a result of differing patient populations enrolled;
more patients in this study failed within earlier radiation field, that
is 60 vs 49%, and more patients in the study by Dimopoulos et al
(2002) had non-squamous histologies, 17 vs 32%.
Results between studies may vary as a consequence of the
inclusion of different proportions of patients exposed to earlier
pelvic radiotherapy, differences in the PS of enrolled patients,
variable inclusion of patients having failed within or outside the
radiation field, doses of drugs applied, and histologic types treated
(squamous vs other). Moreover, in one of the above studies, the
so-called radiation-free interval (time elapsed from previous pelvic
radiotherapy to recurrence, o12 vs X12 months) seemed to have
an important role in outcome after TIP chemotherapy (Zanetta
et al, 1999).
The TIP regimen has been applied as neoadjuvant induction
chemotherapy in patients with previously untreated inoperable
localised cervical carcinoma by the above-referred Italian co-
operative group (Zanetta et al, 1998). After an impressive
pathological response of 34%, the investigators of SNAP (Studio
Neo-Adjuvante Portio) proceeded to a phase II randomised study
of neoadjuvant chemotherapy evaluating TIP vs the doublet of
ifosfamide–cisplatin (IP), and illustrated the superiority of TIP vs
IP with an optimal pathological response (OPR) of 48 vs 22%,
respectively (Buda et al, 2005). Given the above results, a
subsequent randomised study by the same group, SNAP-02,
compared TIP with TP in an identical setting of neoadjuvant
induction chemotherapy and confirmed once again the superior
efficacy of TIP vs TP; OPR 43% vs 23%, respectively (Lissoni et al,
2009). There are no studies so far that have compared in a rando-
mised manner TIP vs TP or IP in advanced/metastatic cervical
cancer. Moreover, in general, there is a paucity of studies compa-
ring three-drug with two-drug regimens in an advanced/metastatic
setting, and only one such study has compared bleomycin–
ifosfamide–cisplatin (BIP) with IP, showing no benefit for the
triplet regimen, pointing rather to the lack of efficacy of bleomycin
as a single agent in advanced cervical cancer (Herod et al, 2000). It
is believed that three-drug regimens, although more efficacious
than two-drug regimens at the expense of increased toxicity, do
not ultimately prolong PFS or OS in advanced/metastatic disease.
In this setting, the TP doublet has shown to prolong median PFS
over single-agent cisplatin (Moore et al, 2004), and the topotecan–
cisplatin two-drug regimen has yielded improved median PFS and
OS (Long et al, 2005).
With increasing numbers of patients who receive concurrent
chemoradiotherapy with cisplatin as standard primary treatment for
locally advanced cervix cancer since 1999–2000, when the
combination emerged as standard, the RR, PFS, and OS rates for
single-agent cisplatin have declined in relapsing patients, and a
relative cisplatin resistance may explain the differences seen in
recent phase III trials comparing combination chemotherapy with
single-agent cisplatin. However, as explained theoretically above, the
TIP combination may overcome resistance to cisplatin at least
partially. A recent GOG study (GOG-204) – the largest phase III
randomised trial in recurrent/metastatic cervical cancer – compared
four platinum-based doublets with the reference arm of paclitaxel–
cisplatin, which was found to be not inferior to the three investi-
gational arms (Monk et al, 2008). Moreover, another GOG phase II
study (GOG-227C) of targeted anti-vascular therapy (bevacizumab
15mgkg
 1) in this patient population showed activity comparable
with cytotoxics and was well tolerated (Monk et al,2 0 0 9 ) .
Our results highlight the important activity of TIP combination
in relapsed/metastatic cervical cancer, even in cases with
recurrences within previously irradiated pelvis, however, at the
cost of increased but manageable haematologic toxicity, and point
to the design of randomised phase III studies comparing TIP with
doublets in appropriately selected patients with advanced/meta-
static cervical cancer.
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